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Abstract 
Polyhydroxyalkanoates (PHAs), a class of biopolyesters produced and stored by 
bacteria, have garnered attention for a number of industrial and biomedical 
applications. The goal of the current study was to extend the use of PHAs to drug 
delivery for the treatment of cancer. As a first step, the cytotoxicity of poly(3-
hydroxy-octanoate-co-10-undecanoate) (PHOU) towards the A549 lung carcinoma 
cell line was determined and nanoparticles were prepared via a single emulsion 
technique. Elution tests, whereby cells were grown in fluid extracts obtained from 
media incubated for 24 hours at 37°C with PHOU films, did not result in any 
significant changes in cellular appearance or proliferation, as determined by 
microscopy and a WST-8 cellular proliferation assay. In contrast, direct contact 
assays that required growth of the cells on the PHOU films, resulted in cell death 
after 24 hours, as indicated by Live-Dead cell staining.  PHOU nanoparticles with 
a size of a ~202 nm and a zeta potential of ~2.7 mV, as established using a Zetasizer 
Nano, were successfully prepared by nanoprecipitation. Ultimately, consistent 
nanoparticle development through single emulsion using PHOU was unsuccessful 
so a miniemulsion technique was used for following nanoparticle development. 
After achieving consistent nanoparticle development through double emulsion, 
folate groups were to be attached to the nanoparticles to specifically target cancer 
cells, but due to polymer cross-linking occurring through that attachment process 
that prevented successful folate attachment, nanoparticle development with new 
PHA polymers was necessary. PHO-N3 was successfully used to develop 
nanoparticles through mini-emulsion, a shorter and more efficient process than 
previous development methods. Through the use of a Zetasizer Nano, the size and 
zeta potential for the PHO-N3 nanoparticles were established as ~108 nm and -80 
mV; suitable values for drug delivery. Although further assessment is required to 
establish the cytoxicity of the nanoparticles, the results provide preliminary 
evidence that nanoparticles of an appropriate size for drug delivery can be prepared.   
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Executive Summary 
 
A successful cell cycle requires a large number of signals to initiate 
cellular activities when necessary, end the cellular activities when appropriate, 
prevent unregulated cell division, and check that all cellular activities are running 
properly. Any cell that does not meet those constraints is considered diseased, 
such as cancer. Cancer is characterized by uncontrolled cell growth and the 
potential to metastasize or invade adjacent tissue. Because of these mutations, 
cancer is a challenging disease to treat, an issue illustrated by mortality rates.  
According to the Center for Disease Control and Prevention, cancer is the 
second leading cause of death in United States. In 2013 alone, there were 580,350 
reported deaths as a result of cancer as well as 1,660,290 new cases according to 
the statistics released by the American Cancer Society. These statistics reaffirm 
the need for continuous study of novel cancer treatment methods. 
Current treatment strategies for cancer are focused on the removal or 
destruction of diseased tissue often through means of radiation and chemotherapy. 
These treatment options are accompanied by a significant level of toxicity which 
has great potential to further medical issues in the afflicted patient. Nanomedicine 
has become a frequent topic of discussion with regard to cancer therapeutics. 
Utilizing cancer drug delivery systems such as liposomes, micelles, or 
nanoparticles  can  increase  an  encapsulated  drug’s  circulatory  stability  thereby  
increasing the probability of the drug arriving at the diseased tissue. Molecules 
that target specific receptors on the tumorous tissue can be attached to polymers 
called polyhydroxyalkanoates (PHAs) in order to enhance specific targeting of the 
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diseased tissue and increase efficacy of the drug. The combination of circulatory 
stability and targeting results in increased efficacy and reduced toxicity. 
Although there has been success in the use of nanocarriers for treatments, 
application of this in a clinical setting is difficult due to the lack of 
biodegradability and biocompatability. In addition, preparation of current drug 
delivery systems is difficult as well as modifying the systems to express desired 
properties.  
The long-term goal of this project is to develop a modifiable drug delivery 
system to treat cancer based on bacteria-produced, environmentally-friendly 
polymers [polyhydroxyalkanoates (PHAs)] with high biodegradability and 
inherent biocompatibility. The objective is to create a PHA-based carrier system 
that can be easily modified to incorporate a targeting molecule, in this case folate, 
that improves selectivity for cancer tissue and that is effective at encapsulating 
and improving the efficacy of an existing anti-cancer drug, paclitaxel (PTX).  My 
hypothesis is that environmentally-friendly, cancer-targeted, PHA nanoparticles 
can be prepared with ease and that these particles can be used to enhance the 
therapeutic efficacy of encapsulated PTX. My hypothesis will be tested by 
pursuing the following specific aims: (1) synthesize and characterize PHA and 
PHA-folate (PHAF) nanoparticles and (2) establish the therapeutic efficacy of 
PTX-loaded PHA and PHAF nanoparticles.  
The respective anticipated results are: (1) biocompatible, cancer-targeted 
nanoparticles can be prepared from PHA and PHAF; and (2) the therapeutic 
efficacy of PTX can be enhanced through incorporation into PHA and PHAF 
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nanoparticles. Also, PTX loaded into actively targeted, PHAF nanoparticles is 
anticipated to be more effective than if loaded into PHA nanoparticles.  
The proposed research provides the foundation for the development of a 
new, effective cancer treatment strategy based on the use of environmentally-
friendly, bacteria produced polymers than can be easily modified to incorporate a 
variety of therapeutics and target many cancer types.  
The materials of interest is from a class of biopolymers called 
polyhydroxyalkanoates (PHAs). PHAs are synthesized and stored by an 
engineered form of E. coli and have received significant attention for industrial 
and biomedical applications. The preliminary steps, verifying that the PHA is a 
suitable polymer for cancer drug delivery and nanoparticle development, have 
been completed.  
The goal of the project is to develop an effective PHA-based drug carrier 
system characterized by high biodegradability and biocompatibility that can 
encapsulate an existing anti-cancer drug called paclitaxel and be modified by 
adding a folate molecule in order to target cancer tissue. In order to do this, the 
current process for developing PHA nanoparticles has been optimized. After 
failing to achieve consistant nanoparticle development through nanoprecipitation 
and double emulsion techniques, a miniemulsion technique was found to produce 
consistent PHA nanoparticles and was optimized for nanoparticle development.   
 
Previous research in the Nomura Laboratory at SUNY ESF using 
engineered E. Coli to produce PHA copolymers was extended beyond saturated 
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fatty acids to include 10-undecenoic, 10-undecynoic acid, and 10-azidodeanoic 
acid monomers.The method currently being used to develop nanoparticles is a 
miniemulsion technique dissolving these PHA copolymers in chloroform and 
adding the polymer-chloroform solution to a separate aqueous SDS solution. The 
mixture is stirred then ultrasonicated and then stirred again to evaporate off excess 
chloroform. By varying the amount of each component used, the nanoparticles 
can be optimized to the proper size and surface charge ideal for delivery and 
cellular uptake.  
In order to assess cellular uptake of nanoparticles, a competitive binding 
assay was conducted by incubating lung carcinoma cells with fluorescently-
tagged nanoparticles and then viewing them by microscopy using a Zeiss 
Axiovert 40 CFL microscope. Due to overlyconfluent cells and the presence of 
folates in the media used, uptake was difficult to correctly assess, although it was 
observed.  
Nanoparticles prepared with PHA copolymers that included terminal 
alkynes were reacted with an azide containing fluorescent tag via click chemistry. 
By attaching azide functional groups to PHA nanoparticles, additional chemistry 
can be used to ultimately attach the folate groups needed for targeting cancer 
cells.  
In addition, the efficacy of the drug delivery system is being evaluated in 
vitro via a WST-8 cell proliferation assay. The anti-cancer effect of PHA-N3 
nanoparticles, PHA nanoparticles, PHA nanoparticles with a folate attached 
[PHAF], free PTX, PTX-loaded, PHA nanoparticles, PTX-loaded, PHAF 
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nanoparticles will be determined using this assay. Currently, anticipated toxicity 
has been experienced in PHA-N3 nanoparticles due to the interactions the azide 
functional groups have with the cells. Other test materials are currently 
undergoing experiment planning or testing for cytotoxicity,   
Following the optimization of the nanoparticle development method, PTX 
will be encapsulated into the PHA nanoparticles and assessed to determine the 
drug encapsulation efficiency. The amount of drug left in the supernatant liquid 
remaining after the nanoparticles are developed will be determined using high 
performance liquid chromatography. Using this value, the loading capacity (mass 
of PTX/mass of nanoparticle) and loading efficiency (percentage of PTX loaded 
into nanoparticle/amount added to polymer solution) can be calculated.  
Overall the purpose of this study is to synthesize and characterize PHA 
and PHAF nanoparticles as well as establish the therapeutic efficacy of drug-
loaded PHA and PHAF nanoparticles. The knowledge gained from this study is 
essential for the development of targeted, environmentally friendly, biopolymer-
based drug delivery systems as a method of cancer therapy characterized by 
increased  efficacy  and  reduced  toxicity.  In  addition  to  this  study’s  significance  
with respect to cancer treatment, the overall reach extends to treatment methods 
for  other  diseases  due  to  the  drug  carrier  system’s  ease  of  manipulation. 
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Chapter 1: Introduction 
Current treatment strategies for cancer often employ a combination of 
established methods to achieve the greatest anti-cancer effect. While these 
methods are effective at destroying cancer cells, they are often accompanied by a 
significant amount of toxicity. Polyhydroxyalkanoates (PHAs) are a class of 
biodegradable biopolyesters produced and stored by bacteria that have received 
significant attention for industrial biomedical applications. The number of carbon 
atoms in the individual PHA monomers is the greatest determinant of a PHA 
polymer’s  physical  properties.  These  PHA  monomers  are  incorporated  by  
bacterial enzymes into polymer chains (figure 1). PHA polymers can either be of 
short-chain-length (SCL) with 3 – 5 carbons or medium-chain-length (MCL) with 
6 – 14 carbons1,2. PHA copolymers have proven to have material properties 
similar to polyethylene and polypropylene and are of special interest for their 
biocompatibility1,2. Currently, PHAs have been used in biomedical applications 
such as sutures, screws, surgical mesh, stents3, and drug delivery4-10 and this study 
aims to expand their role in drug delivery. 
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PHAs were originally found present in bacteria in the 1920s11 and since 
then, the process has been adapted for the laboratory environment. As shown in 
figure 2, bacteria are fed fatty acids of varying chain lengths to produce PHA 
monomers of different sizes. In fermentation chambers, PHAs are developed 
within the bacteria, which are then lysed for retrieval and purification of the PHA. 
The resulting product is a bioplastic with material properties largely determined 
by the monomer composition of the PHA. One such property, biodegradability, is 
PHA Production by Engineering E.Coli Bacteria 
 
 
 
 
 
 
Figure 1. Production of PHA Monomers by Engineering E.  coli Engineered E. coli can 
produce PHA copolymers from fatty acids with defined repeating unit compositions and material 
properties.1 
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inherent of all PHA polymers and an important characteristic of environmentally-
friendly plastics. 
 
The Nomura Research Group at SUNY ESF engineered a strain of 
Escherichia coli to produce PHA polymers with specifically defined repeating 
chains from fatty acids12,13. Having the ability to produce consistent repeating 
polymer composition allows for the development of PHA polymers with desired 
material properties. Additionally, functionalized PHAs can be modified through 
thiol-ene and copper-catalyzed click chemistry to attach fluorescent tags or folate 
groups to visualize uptake by the cells or specifically target cancer12. 
Nanoparticles designated for drug delivery applications, like the ones used in this 
study, require polymers with biodegradable or biocompatible properties, such as 
PHA.  
Polyhydroxyalkanoates in Biomaterials 
 
 
 
 
 
 
Figure 2. Life Cycle of PHA Polymers in Biomaterials. PHAs are produced within bacteria in 
both nature and the laboratory environment. The polymer is retrieved and purified and the 
resulting bioplastic is used for biomaterial applications. Ultimately, the polymer is biodegradable 
and breaks down back into the environment where it is nontoxic. 
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Polymer nanoparticles can be developed through a variety of methods15, 
but the two main methods used in this study were nanoprecipitation and 
miniemulsification. Nanoprecipitation, a solvent displacement method, involves 
dissolving the polymer from which you wish to make nanoparticles in an organic 
solvent, before slowly adding the organic solution to an aqueous solution of non-
solvent with surfactant. The nanoparticles are produced when the polymer solvent 
quickly diffuses in the non-solvent phase as drops of the organic solution are 
added. The tension between the solvent and non-solvent phases decreases when 
the two phases are mixed so the nanoparticle surface area increases and 
nanoparticles precipitate out. Miniemulsification involves dissolving the polymer 
in an organic solvent and mixing it with a solution of water and a surfactant. The 
mixture is then subjected to high shear through ultrasonication to produce the 
emulsified nanoparticles. The organic solvent is removed by heating the solution 
to evaporate the solvent out. Anti-cancer drugs such as paclitaxel21-24 can be 
incorporated into the nanoparticles simply by dissolving the drug along with the 
polymer in the first step of the nanoparticle development process. 
One of the greatest challenges of cancer treatment is tempering the anti-
cancer  effect  of  the  treatments  used  such  that  healthy  cells  aren’t  damaged.  One  
solution to this is to develop nontoxic treatment methods and ensure that only the 
diseased site is effected. Using a family of chemical reactions referred to as click 
chemistry, targeting groups and other functional moieties can be directly attached 
to PHA polymers that contain functional groups18,19, before or after nanparticle 
development. Breast  cancer,  for  example,  overexpresses  folate  receptor  α  so  by  
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attaching folate groups to PHA nanoparticles, breast cancer tissue can be 
specifically targeted16,17. Since PHA nanoparticles are biocompatible and 
biodegradable, toxicity is limited as paclitaxel is housed within the PHA 
nanoparticle, protecting healthy cells as the drugs move through the body. 
Furthermore, the addition of folate groups increases the anti-cancer drug 
concentration at the diseased tissue rather than healthy tissue. 
Brain cancer, on the other hand, is significantly more difficult to treat due 
to the presence of the blood-brain barrier preventing the transportation of 
necessary anti-cancer drugs to the diseased site. Penetration and transportation 
across the blood-brain barrier using drug-loaded carrier systems can be facilitated 
and enhanced by using multi-function PHA nanoparticles25 coated with lactoferrin 
and transferrin, receptors overexpressed by brain endothelial cells 26. 
Additionally, by using certain surfactants in the nanoparticles development 
process, the absorption of apolipoprotein A-1 in the blood by the nanoparticles 
can be encouraged, further enhancing blood-brain barrier transport27. Finally, anti-
epidermal growth factor antibodies and angiopep-2 ligands can be attached to 
PHA nanoparticles for additional blood-brain barrier transport enhancement and 
the specific targeting of brain cancer due to the overexpression of angiopep-2 
ligand receptors in glioblastoma cells28-33. Ultimately, the result is a nontoxic, 
environmentally-friendly, targeted drug delivery system. 
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Chapter 2: Materials and Methods 
 The first step in this study was to establish the cytotoxicity of PHA 
polymers themselves before nanoparticles development. Indirect contact assays 
were used to determine whether elutions of the polymer in cell culture media are 
toxic to the cells. For this assay, PHOU was the PHA polymer used along with 
lung cancer cells of A549 cell line which uses F-12K media with 10% fetal 
bovine serum (FBS). Cells were cultured in four wells of a 24-well culture plate 
and incubated for 24 hours. The polymer was sterilized by submerging it a 70% 
ethanol solution for 30 minutes and then dried on a hot plate so that the ethanol 
was no longer present. After drying, the polymer was submerged in 15 mL of the 
culture medium and incubated for 24 hours at 37oC. After 24 hours, the culture 
media was removed from the wells of the well plate and replaced with elutions of 
the polymer-contaminated media for two of the wells, and non-contaminated 
media for the other two wells. The cells in the well-plate were incubated again for 
24 hours.  
The indirect contact assay (figure 3) was performed using green (for live 
cells) and red (for dead cells) fluorescent dyes from the Life Technologies 
Live/Dead Assay which included calcein AM and ethidium homodimer-1. A 
Live/Dead  stain  solution  was  made  from  the  two  dyes  along  with  Dulbecco’s  
phosphate-buffered saline (D-PBS). The media was removed and replaced with 
Live/Dead stain for each well. After incubating the cells again for 45 minutes, the 
Live/Dead stain was removed and cells were rinsed with D-PBS. Using 
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fluorescence microscopy, images of live and dead cells can be obtained with 
green cells representing healthy cells and red cells representing dead cells.  
 
The next step was to conduct a direct contact assay (figure 4) to determine 
whether cytotoxicity was experienced for cells cultured directly on PHA. The 
polymer was initially sterilized in the same manner as in the indirect contact assay 
and then adhered to the bottom of a 6 well plate. Cells of A549 lung carcinoma 
cell line were cultured on top of the polymer and incubated for 24 hours at 37oC. 
After 24 hours, the media was removed and the same Live/Dead stain from the 
indirect contact assay was added. The cells were again incubated at 37oC for 45 
minutes and then rinsed with D-PBS. The polymer was carefully removed from 
the well plate with sterilized tweezers and placed on a glass slide for observation 
using fluorescence microscopy.  
 
 
 
 
      
(a)        (b)     (c) 
 
 
 
 
 
  (d)     (e)          (f) 
  
Indirect Contact Assay 
Figure 3. Indirect Contact Assay for PHA and A549 Lung Carcinoma Cells (a) Sterilization of 
polymer in 70% EtOH for 24 hours (b) Drying PHA to remove EtOH (c) Addition of PHA-
contaminated media elutions to two wells of A549 lung carcinoma cells. Incubate 24 hours at 37oC. (d) 
Two wells of cells containing PHA-contaminated media and two wells containing uncontaminated 
media. Incubate 24 hours at 37oC (e) Media from all wells replaced with Live/Dead Stain. Incubate 45 
minutes at 37oC. (f) Observe live and dead cells with fluorescence microscopy 
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After establishing PHA cytotoxity, successful nanoparticle development 
was the next step of the study. Intially, PHA nanoparticles were developed using a 
solvent displacement method known as nanoprecipitation (figure 5). PHOU was 
dissolved in acetone and then added dropwise to aqueous solution (PBS/Pluronic 
F-68 or Water/Pluronic F-68 was used). The mixture was stirred for 24 hours at 
room temperature at 1200 rpm using a stir bar and magnetic stir plate to allow the 
acetone to evaporate out. After 24 hours, the mixture was filtered using a 0.45 
micron nylon filter and then ultracentrifuged for 1 hour at 51354 x G and 4oC. 
The supernatant was discarded and the nanoparticles were resuspended in 9 mL 
deionized water for additional rinsing by centrifuging again under the same 
conditions. Following the second centrifugation, the supernatant was discarded 
and the nanoparticles were resuspended in 3 mL of deionized water.  
Figure 4. Direct Contact Assay for PHA and A549 Lung Carcinoma Cells (a) Sterilization of 
polymer in 70% EtOH for 24 hours (b) Drying PHA to remove EtOH (c) Adherence of PHA to well 
of 6-well plate (d) Cells cultured on PHA in well. Incubate for 24 hours at 37oC (e) Media replaced 
with Live/Dead Stain. Incubate 45 minutes at 37oC. (f) PHA placed on glass slide for microscopy (g) 
Observe live and dead cells with fluorescence microscopy 
Direct Contact Assay  
 
 
 
      
(a)             (b)          (c)       (d) 
 
 
 
 
 
            (e)         (f)      (g) 
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Ultimately, due to inconsistencies with the nanoparticles developed 
through the nanoprecipitation method, other methods of nanoparticle development 
had to be explored. Using the miniemulsion method shown in figure 6, 60 mg of 
PHA polymer was dissolved in 1.0 mL of chloroform which was then added to 
2.73 mL aqueous sodium dodecyl sulfate (SDS) (4.44 mg/mL). The mixture was 
then stirred at room temperature for an hour on a magnetic stir plate resulting in 
monodisperse chloroform droplets containing the dissolved polymer, separated 
from water by the SDS. Ultrasonication was then used (40% amplitude, 4 second 
pulse, 1 minute) to emulsify the droplets and form the PHA nanoparticles. 
Chloroform is then removed by heating the emulsion at 70oC for 2 hours, leaving 
the PHA nanoparticles suspended in water.  
Nanoparticle Development: Nanoprecipitation 
 
 
 
 
 
 
 
 
(a)            (b)        (c) 
Figure 5. Nanoparticle Development through Nanoprecipitation Method. (a) Organic Phase 
added drop-wise to aqueous phase (b) Polymeric Nanoparticles suspended in Aqueous Phase (c) 
Polymeric Nanoparticles suspended in deionized water 
Centrifugation 
& Filtration Solvent Evaporation 
10 
 
 
 
Following nanoparticle development, it was necessary to characterize the 
nanoparticles. This was done by quantitatively measuring size and zeta potential 
(the surface electric charge of the nanoparticle) through dynamic light scattering 
using a Zetasizer Nano device. Atomic force microscopy and scanning electron 
microscopy was used to observe the shape of the nanoparticle and confirm the 
size.  
Once the nanoparticles were found to be of appropriate size and zeta 
potential for drug delivery applications, functional groups were attached using 
click chemistry. Fluorescent tags were attached to PHA nanoparticles and then 
added to the media used to culture breast cancer cells of the MT3 cell line (figure 
7). After incubating the cells with the PHA nanoparticle-contaminated media for 
24 hours at 37oC, fluorescent microscopy was used to observe the PHA 
nanoparticles with the cells.  
Nanoparticle Development: Miniemulsion 
 
 
 
 
 
 
 
 
(a)    (b)  (c)    (d)         (e) 
Figure 6. Nanoparticle Development through Miniemulsions. (a) PHA polymer dissolved in 
Chloroform added to aqueous SDS (b) Pre-emulsification: Mixture stirred at RT for 1 hour (c) 
Ultrasonication: Mixture emsulsified forming PHA nanoparticles (d) Emulsion heated for 2 hours 
at 70oC to remove chloroform (e) PHA nanoparticles dissolved in water 
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Another step after nanoparticle development is to establish the 
cytotoxicity of the nanoparticles themselves. Using a WST-8 assay depicted in 
figure 9, nanoparticle cytotoxicity can be determined based on the metabolic 
activity of the cells. Lung or breast cancer cells were cultured in two rows of 7 
wells in a 96-well plate and incubated for 24 hours at 37oC. A dilution series 
(figure 8) was made by adding 200 µL of PHA nanoparticle solution to 800 µL of 
cell culture media in a 1.5 mL microcentrifuge tube. 500 µL of cell culture media 
was added to 5 additional 1.5 mL microcentrifuge tubes as well. After mixing the 
PHA nanoparticle solution in media well, 500 µL was removed and mixed with 
the edia of the next tube in succession. This process was repeated until the final 
tube contained 1000 µL total volume.  
Click Reaction of Functionalized Nanoparticles 
 
 
 
 
 
 
 
 
 
 
Figure 7. Copper Catalized Click Reaction to produce Fluorescently-Tagged Nanoparticles. 
(a) Red fluorescent tag (b) Alkyne-modified PHA nanoparticles (c) Fluorescently-tagged PHA 
nanoparticles 
(a)        (b)    (c) 
12 
 
 
 
The dilution series was added in 200 µL aliquots to each respectively 
numbered experimental well of the 96-well plate. The 7th well of each row is the 
control well and media was replaced with 200 µL of normal culture media. The 
8th well was designated as a blank well and remained on touched as this point. 
The cells were then incubated again for 24 hours at 37oC. After 24 hours, the 
media and nanoparticles within each well were removed and replaced with 100 
µL of media and 10 µL of CCK-8  reagent  from  Dojindo’s  Cell  Counting  Kit-8. 
After incubating once more for 1 hour, absorbance values were obtained using a 
plate reader and a wavelength of 450 nm.  
Dilution Series 
 
 
 
 
 
 
 
 
 
Figure 8. Dilution Series of PHA Nanoparticles in Cell Culture Media. The volume labels 
beneath the graphics depict initial microcentrifuge tube contents and volume labels within the red 
lines show the movement of the PHA nanoparticles and nanoparticle/media mixture through the 
dilution. The result is 6 tubes containing an exact fraction of the initial nanoparticle. For each 
tube, the concentration compared to the original nanoparticle solution respectively is (1) 1/5 (2) 
1/10 (3) 1/20 (4) 1/40 (5) 1/80 (6) 1/160 
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WST-8 Assay 
 
 
 
 
(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
(d) 
Figure 9. WST-8 Assay for PHA Nanoparticles and Cancer Cells. (a) Cells cultured in two 
rows of 7 wells each and incubated for 24 hours at 37oC  (b) Dilution series added to experimental 
wells and media replaced in control well (c) 10 µL of CCK-8 reagent and 100 µL culture media 
added to each well including blank well. Incubate 1 hour at 37oC  (d) Obtain absorbance values 
using plate reader at 450 nm wavelength 
1     2     3      4     5     6      C     B  
1     2     3      4     5     6      C     B  
1     2     3      4     5     6      C     B  
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Chapter 3: Results 
The polymer, poly(3-hydroxy-octanoate-co-10-undecanoate) (PHOU), 
was shown to be nontoxic to the A549 cell line through the indirect contact assay. 
Live and dead cells are indicated by green and red fluorescence, respectively. This 
is as a result of the components used to develop the Live/Dead stain. Calcein AM, 
for example, is well retained in live cells, and produces green fluorescence in 
those cells. Ethidium homodimer-1, however, associates with damaged cell 
membranes that are present in dead cells and fluoresces with the nucleic acids that 
are no longer protected by the damaged cell membranes. As a result of these dyes 
and their associated reactions, only live cells can be depicted as green and only 
dead cells can show red. As seen in figure 10, lung cancer cells of the A549 cell 
line fluoresce green and no red fluorescence is observed, signifying a lack of 
cytotoxicity through indirect contact.
 
PHOU was shown to result in cell death for the A549 cell line through the 
direct contact assay. Since the stain used for this assay is the same as the indirect 
contact assay, resulting pictures from fluorescence microscopy can be analyzed in 
Indirect Contact Assay Results 
 
 
 
 
 
 
 
 
 
       Control    PHOU 
 Figure 10. Live/Dead Assay for PHOU and A549 lung carcinoma cells. Indirect contact assays 
were conducted with live/dead staining and fluorescence microscopy was used to show that 
elution tests did not result in any changes in cellular appearance or proliferation after incubation 
for 24 hours at 37oC. 
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the same manner. As seen in figure 11, lung cancer cells of the A549 cell line 
fluoresce red with very little green fluorescence present, signifying severe cell 
death. 
 
 Nanoparticles were characterized by their size and zeta potential using a 
Zetasizer Nano. The Zetasizer Nano uses dynamic light scattering to determine 
particle size. By shining a monochromatic light source through a clear solution of 
dissolved particles, the resulting light intensity patterns are captured by a 
photoreceptor and can be correlated to particle size which is calculated and 
displayed along with the size profile of the particle by a computer and 
accompanying software. The Zetasizer Nano measures the Brownian motion of 
the particles through dynamic light scattering and uses the Stokes-Einstein 
equation to relate the motion of the particles to particle size. For nanoparticles to 
be suitable for drug delivery applications, they must ideally must be 100 nm in 
diameter (size) and have an absolute zeta potential value greater than 30 mV (real 
zeta potential value >30mV or <-30 mV). Nanoparticles were successfully 
Direct Contact Assay Results 
 
 
 
 
 
 
 
 
 
           Control               PHOU 
Figure 11. Direct Contact Assay for PHOU and A549 Lung Carcinoma Cells. Cells were 
cultured directly on PHOU. Direct contact assays were conducted with Live-Dead staining. 
Fluorescent microscopy was used to show severe death after incubation at 37oC for 24 hours. 
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developed using the nanoprecipitation method, but consistent sizes and ideal zeta 
potential values were unable to be achieved as shown in table 1.  
 
 
 Atomic Force Microscopy (AFM) was used to confirm the presence of 
PHOU nanoparticles and verify the relative size (Figure 12). A small glass slide 
the size of a penny was prepared for AFM by placing a 10 µL drop of PHOU 
nanoparticle solution on the slide and allowing the water to evaporate, leaving 
PHOU nanoparticles dried on the slide. The nanoparticles were observed using an 
atomic force microscope which develops a picture of the material on the AFM 
slide through the force response of a needle interacting with the test material. A 
scale can be used to associate the diameter of the particles in the pictures to the 
real particle size. 
PHOU Nanoparticle Characterization: Size and Zeta Potential 
Table 1. Size and Zeta Potential Measurements for PHOU Nanoparticles Developed 
Through Nanoprecipitation. After a variety of attempts at nanoparticle development through 
nanoprecipitation with size and zeta potential ideal for drug delivery (~100 nm; >30 mV or < -
30mV), consistent and appropriately sized and charged nanoparticles were not achieved. 
PHOU 
(mg)
Acetone 
(mL)
Pluronic F-68 
(wt% )
PBS 
(mL)
Water 
(mL)
Average 
Size (nm)
Zeta 
Potential 
(mV)
PDI
25.0 5.0 4.0 15.0 0.0 248.70 -15.30 0.2523
9.0 3.0 4.0 10.0 0.0 186.75 -1.83 0.2495
9.0 3.0 5.0 10.0 0.0 175.40 -19.00 0.2510
9.0 3.0 10.0 10.0 0.0 256.65 -25.50 0.0870
15.0 3.0 10.0 10.0 0.0 306.40 -4.560 0.1050
9.0 3.0 1.0 0.0 10.0 143.39 -19.23 0.0287
9.0 3.0 10.0 0.0 10.0 194.27 -12.82 0.0295
9.0 9.0 0.1 0.0 10.0 90.51 -10.17 0.1022
9.0 9.0 0.5 0.0 10.0 46.43 -7.53 0.4353
9.0 9.0 1.0 0.0 10.0 142.02 -19.77 0.0317
9.0 9.0 10.0 0.0 10.0 109.30 -11.90 0.0560
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 Scanning Electron Microscopy was also used to observe the shape and 
confirm the presence of PHOU nanoparticles. PHOU nanoparticles were freeze-
dried and prepared on SEM sample holders and then observed using a scanning 
electron microscope. As shown in figure 13, SEM images of PHOU nanoparticles 
confirm inconsistent nanoparticle development.  
AFM Images of PHOU Nanoparticles 
 
 
 
 
 
 
Figure 12. Atomic Force Microscopy Images of PHOU Nanoparticle Developed Through 
Nanoprecipitation. The presence of PHOU nanoparticles was confirmed and relative size verified 
by AFM. 
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 After PHOU nanoparticles developed through nanoprecipitation proved to 
be too inconsistent for drug delivery applications, a new method was used called 
miniemulsion that successfully achieved consistent nanoparticle development 
with nanoparticles of appropriate size and zeta potential for drug delivery. PHA 
nanoparticles developed using miniemulsions used the PHA polymer, PHO-N3, 
SEM Images of PHOU Nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           (b) 
 
Figure 13. Scanning Electron Microscope Images of PHOU Nanoparticles Developed 
Through Nanoprecipitation. SEM confirms inconsistent nanoparticle development with PHOU 
nanoparticles developed through nanoprecipitation. (a) The spherical shape of the nanoparticles 
shows nanoparticle development however agglomeration suggests the freeze-drying procedure 
could be improved. (b) The unrecognizable shape suggests that the formation cannot sustain its 
shape and therefore is not ideal for drug delivery. 
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an azide-terminated PHA. These nanoparticles were measured using a Zetasizer 
Nano in the same manner as the previous nanoparticles. As shown in Table 2, 
PHO-N3 nanoparticles developed through miniemulsions achieved sizes and zeta 
potentials ideal for drug delivery.  
 
 Functional group-modified PHA nanoparticles were developed using a 
several different functional groups through miniemulsion with low polydispersity 
and appropriate  size  for  drug  delivery  applications  (table  3).  Although  it’s  not  
shown, zeta potential for each functionalized nanoparticle was found to be around 
-70 mV which is consistent with the charge of the SDS incorporated in the 
nanoparticle solution. 
 
As a demonstration of the ability to perform click reactions on 
functionalized nanoparticles, fluorescent tags were attached (figure 5) and cellular 
uptake was observed. Figure 14 depicts red, fluorescently tagged, alkyne modified 
PHA nanoparticles within breast cancer cells of the MT3 cell line.  
PHO-N3 Nanoparticle Characterization: Size and Zeta Potential 
 
 
 
 
 
 
Table 2. Size and Zeta Potential Measurements for PHO-N3 Nanoparticles Developed 
Through Miniemulsions. Consistent PHO-N3 nanoparticles of appropriate size and zeta potential 
for drug delivery were achieved and measured using a Zetasizer Nano. 
PHO-N3 
(mg)
Chloroform 
(mL)
Aqueous SDS (mL) 
[4.44 mg/mL]
Average Size 
(nm)
Average Zeta 
Potential (mV) PDI
60.0 1.0 2.73 103.4 -79.53 0.0477
Functionalized PHA Nanoparticle Characteristics 
Polymer Functional Group Size (nm) PDI 
PHO Alkene 88.4 0.09 
 Alkyne 136.8 0.09 
 Azide:Alkyne (1:1) 133.5 0.016 
 
Table 3. Size and Zeta Potential of Functionalized PHA Nanoparticles. Successful 
development of functionalized PHA nanoparticles was achieved with low polydispersity and 
suitable sizes for drug delivery applications. 
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Nanoparticle measurements were taken again 3 days after initial 
nanoparticle development to assess stability. Zetasizer Nano results show 
comparable results for size and zeta potential for both periods (figure 15). 
Cellular Uptake of Functionalized PHA Nanoparticles 
 
 
 
 
 
 
Figure 14. Cellular Uptake of Fluorescently Tagged PHA Nanoparticles by Breast Cancer 
cells. Alkyne-modified PHA nanoparticles, fluorescently-tagged through click chemistry were 
observed within breast cancer cells of the MT3 cell line using fluorescence microscopy 
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Size and Zeta Potential: 24 and 72 Hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
      
       (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
 
         (b) 
Figure 15. Size and Zeta Potential of PHO-N3 Nanoparticles at 24 and 72 hours. Size and 
zeta potential remain consistent (a) Size and zeta potential at 24 hours (b) size and zeta potential 
at 72 hours 
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 After successful nanoparticle development through miniemulsions, the 
cytotoxicity of the functionalized nanoparticles needed to be established. Initial 
WST-8 assays resulted in an IC50 curve (figure 16) that allowed us to determine 
the concentration at which 50% of cell death is observed, or the IC50 
concentration. For PHO-N3 nanoparticles, the IC50 concentration value was 
found to be 2.6815 mg/mL. From additional WST-8 assay results, no cytotoxicity 
of was shown for PHO-N3 nanoparticles toward the MDA-MB-231 breast cancer 
cell line despite increasing concentration (figure 17). 
 
IC50 Curve for PHA Nanoparticles 
 
 
 
 
 
 
Figure 16. IC50 Curve for PHO-N3 Nanoparticles and MDA-MB-231 Breast Cancer Cells. 
Based on the absorbance values from a WST-8 Assay assessing the cytotoxicity of PHO-N3 
nanoparticles and MDA-MB-231 cells, an IC50 curve was established and an IC50 value of 
2.6815 mg/mL was obtained. IC50 represents the concentration at which 50% of cell death 
occurs. On y axis, 1 represents no cytotoxicity and 0 represents total cell death. Values above 0.8 
are considered nontoxic. 
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WST-8 Assay Results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            (a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           (b) 
 
Figure 17. WST-8 Assay Results for PHO-N3 Nanoparticles and MDA-MB-231 Cell Line. 
PHO-N3 nanoparticles have shown no cytotoxicity (absorbance < 0.8) with increasing 
concentration compared to widely-accepted PLGA nanoparticles. 
0
0.2
0.4
0.6
0.8
1
1.2
0.000 0.045 0.091 0.181 0.363 0.725 1.450
Re
la
tiv
e
 A
b
so
rb
a
nc
e
Concentration (mg/mL)
24 
 
 
Chapter 4: Discussion 
 While cells of the A549 cell line experienced no cytotoxicity through the 
indirect contact assay, cell death was observed when the cells were cultured 
directly on top of the PHOU polymer. This is believed to be as a result of the 
presence of bacterial microbes present within the folds of the polymer which 
protected the microbes from removal when the polymer was purified before the 
assay. The presence of toxic components within the polymer as well as cross-
linking within the polymer structure and in general a lack of consistency among 
results for PHOU nanoparticles prompted nanoparticle development using another 
PHA, polyhydroxyoctanoate (PHO).  
 Although the material itself is partially responsible for the inconsistent 
nanoparticle development, the process of nanoprecipitation itself was found to be 
an inconsistent method altogether. Through nanoprecipitation, a wide range of 
sizes were produced even among nanoparticles developed identically. Zeta 
potential values were inconsistent and did not fall within the suitable range for 
drug delivery applications. The miniemulsion process, however, was not only an 
effective method for consistent nanoparticle development that produced 
appropriately sized and charged particles for drug delivery, but also a more 
efficient method.  
 The miniemulsion process requires a max development time of 4 hours 
from preparation through chloroform removal compared to the 28 plus hours 
required for nanoprecipitation. Steps for nanoprecipitation, such as centrifugation 
was the primary inconsistent element of the nanoparticle development process 
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since high speeds were required to separate out the nanoparticles. Often, the 
resulting nanoparticle pellet would quickly begin dissolving back into the 
supernatant after centrifugation, resulting in loss and ocacasionally negating the 
centrifugation step altogether. Monodisperse chloroform droplets containing 
dissolved PHA, separated from water by SDS are readily made in the 
miniemulsion process due to the kinetic behavior of the reagents involved and 
then a high shear energy source (in this case ultrasonication) is used to complete 
the emulsion and form the nanoparticles. At this point the nanoparticle solution 
can be purified simply by boiling out the chloroform. The result was a more 
consistent, ideally characterized nanoparticle carrier system than that developed 
by nanoprecipitation. 
 With regards to the cellular uptake of the fluorescently-tagged PHA 
nanoparticles, initial challenges were presented as a result of the presence of 
folates in the culture media used for the cells. Since breast cancer cells 
overexpress folate receptors, folate groups are an ideal targeting group for 
nanoparticle carrying drugs intended to treat breast cancer. However due to the 
presence of folates in the fetal bovine serum component of the culture medium, 
the presence of folate-functionalized nanoparticles within the breast cancer cells 
was not as pronounced.  
 The WST-8 assays provided some challenges as well. Initially, the assay 
was conducted successfully resulting in an IC50 curve and the establishment of an 
IC50 value (figure 16). Following attemps, however, resulted in unusable results 
in which absorbance values for experimental wells were found to be greater than 
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that of the control well. One potential cause of the unusual absorbance values 
found for experimental wells was the presence of nanoparticles within the wells 
during analysis with a plate reader. The media containing the test material for 
WST-8 assays is supposed to be removed before the addition of the CCK-8 
reagent, however wells were inadequently rinsed, resulting in the presence of 
nanoparticles within the wells still during plate reading. The presence of 
nanoparticles skewed the absorbance values determined by the plate reader 
implying that cell proliferation was greater for experimental wells than in the 
control wells. Additional assays were performed with adequate removal of PHA 
nanoparticles and usuable result were obtained again that displayed no 
cytotoxicity (figure 17). Normally, azide would be toxic to cells but by 
conjugating the azide to form PHO-N3, cytotoxicity is eliminated. 
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Chapter 5: Conclusion and Future Work 
Consistent development of PHA nanoparticles with size and zeta potential 
suitable for drug delivery was achieved. Despite initial concerns regarding PHA 
cytotoxicity, functionalized PHA nanoparticles were found to display no 
cytotoxicity to MDA-MB-231 breast cancer cells. Highly efficient click chemistry 
reactions were used to successfully attach functional groups to PHA 
nanoparticles. Through click chemistry, fluorescent tags were attached to alkyne-
modified PHA nanoparticles and fluorescence microscopy was used to observe 
cellular uptake of these functionalized nanoparticles by the MT3 breast cancer 
cell line. While further work is needed to assess the drug-loading efficiency, 
stability, perform differential scanning calorimetry, and further establish PHA 
nanoparticle cytotoxicity, this study has shown that functionalized PHA 
nanoparticles with applications in targeted drug delivery can be developed.  
 Further work must be done to assess the stability of the PHA 
nanoparticles. By taking size and zeta potential measurements of PHA 
nanoparticles daily for a week and then once a week for a 3 months, size and zeta 
potential stability can be assessed. Thermal stability and material characteristics 
of the PHA nanoparticles can be established through differential scanning 
calorimetry. A thermal analyzer called a differential scanning calorimeter is used 
to determine material properties such as glass transition temperature and melting 
point. By knowing the thermal properties of the PHA nanoparticles, 
determinations can be made regarding the stability of the nanoparticles under a 
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variety of conditions. The most of relevant of which being the biological 
conditions found present in the human body.  
Anti-cancer drugs such as PTX can be loaded within the PHA 
nanoparticles by dissolving the drug simulataneously with the polymer in 
chloroform when developing the nanoparticles through miniemulsions. The 
amount of drug left in the supernatant liquid remaining after the nanoparticles are 
developed will be determined using high performance liquid chromatography. 
Using this value, the loading capacity (mass of PTX/mass of nanoparticle) and 
loading efficiency (percentage of PTX loaded into nanoparticle/amount added to 
polymer solution) can be calculated.  
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